Aspartame vs Acesulfame Potassium: which is worse?

What is Aspartame?

Aspartame is a low-calorie synthetic dipeptide sweetener composed of two amino acids — phenylalanine and aspartic acid — bonded with methanol. When metabolized, it breaks down into these three components. It is approximately 200 times sweeter than sucrose, so tiny amounts provide significant sweetness with almost no calories.

What is Acesulfame Potassium?

Acesulfame potassium (Ace-K) is a calorie-free synthetic sweetener approximately 200 times sweeter than sucrose. It contains a potassium atom bonded to an oxathiazinone dioxide ring structure. It is heat-stable and non-metabolized, passing through the body unchanged. Often blended with sucralose or aspartame to mask bitter aftertaste.

Documented risks

Aspartame: Aspartame has been one of the most studied food additives in history, with over 200 regulatory studies reviewed by multiple agencies. The FDA and EFSA have repeatedly reaffirmed its safety at permitted levels for the general population. IARC classification controversy (2023): In July 2023, IARC classified aspartame as Group 2B (possibly carcinogenic to humans), based primarily on limited evidence from human epidemiological studies associating aspartame intake with hepatocellular carcinoma (liver cancer) in some observational studies. Notably, the WHO Joint Expert Committee on Food Additives (JECFA) simultaneously re-evaluated aspartame and maintained the ADI at 40 mg/kg/day, concluding that the evidence does not establish that aspartame causes cancer at typical intake levels. This rare split between IARC (hazard identification) and JECFA (risk assessment) created significant public confusion. Phenylketonuria (PKU): Aspartame is definitively harmful for individuals with phenylketonuria — a genetic disorder affecting phenylalanine metabolism. People with PKU cannot process phenylalanine normally, and aspartame consumption can cause severe neurological damage. This is why all aspartame-containing products must carry a PKU warning on US and EU labels. Methanol release: aspartame metabolism releases methanol (~10% by weight). Critics including independent researcher Woodrow Monte have argued that methanol from aspartame is harmful, citing methanol's conversion to formaldehyde and formic acid in the body. However, methanol released from aspartame is a fraction of the methanol obtained from fresh fruit juices, and regulatory agencies consider the amounts released too small to be clinically significant. Gut microbiome concerns: a 2021 Cell study found that aspartame and other sweeteners altered gut microbiome composition and glucose tolerance in humans. These microbiome effects are an emerging area of research.

Acesulfame Potassium: The safety database for Ace-K is considered less comprehensive than that for other sweeteners. Critics have argued that the original FDA approval studies from the 1970s-1980s were insufficient in quality and length to definitively establish long-term safety. The Center for Science in the Public Interest (CSPI) has petitioned for additional testing. Two rat studies found statistically significant increases in lung tumors (in male rats) and mammary tumors at high doses. Regulatory agencies have argued these doses far exceeded typical human exposure and attributed the tumor findings to other factors. However, the question of whether Ace-K's approval studies meet modern standards has been raised by independent researchers. A 2021 study in Cell found that Ace-K and other non-nutritive sweeteners altered gut microbiome composition and affected glucose tolerance in some human participants. Ace-K specifically was associated with changes in gut bacteria that correlated with glycemic effects. Neurological concerns: some animal studies suggest Ace-K may affect brain neurotransmitter systems. A 2013 study in PLoS ONE found that Ace-K consumption in pregnant mice altered offspring postnatal taste preference and increased weight gain, suggesting potential transgenerational effects. These findings were at doses exceeding typical human intake. Endocrine disruption potential has been raised in some in vitro studies, but comprehensive human data are lacking.